Comprehensive Middle-Down Mass Spectrometry Characterization of an Antibody–Drug Conjugate by Combined Ion Activation Methods
- 22 June 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 92 (14) , 9790-9798
Abstract
Antibody–drug conjugates (ADCs) are an increasingly prevalent drug class utilized as chemotherapeutic agents. The complexity of ADCs, including their large size, array of drug conjugation sites, and heterogeneous compositions containing from zero to several payloads, demands the use of advanced analytical characterization methods. Tandem mass spectrometry (MS/MS) strategies, including a variety of bottom-up, middle-down, and even top-down approaches, frequently applied for the analysis of antibodies are increasingly being adapted for antibody–drug conjugates. Middle-down tandem mass spectrometry, often focusing on the analysis of ∼25 kDa protein subunits, offers the potential for complete sequence confirmation as well as the identification of multiple conjugation states. While middle-down studies have been extensively developed for monoclonal antibodies, middle-down characterization of ADCs has been limited by the high complexity of the drug molecules. This study seeks to bridge the gap by utilizing a combination of 193 nm ultraviolet photodissociation (UVPD), electron-transfer dissociation (ETD), and electron-transfer/higher-energy collision dissociation (EThcD). The compilation of these MS/MS methods leads to high sequence coverages of 60–80% for each subunit of the ADC. Moreover, the combined fragmentation patterns provide sufficient information to allow confirmation of both the sequence of the complementarity-determining regions and the payload conjugation sites.Keywords
Funding Information
- Division of Chemistry (CHE-1402753)
- Welch Foundation (F-1155)
This publication has 51 references indexed in Scilit:
- Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successesJournal of Cellular Physiology, 2018
- Fate of Antibody-Drug Conjugates in Cancer CellsJournal of Experimental & Clinical Cancer Research, 2018
- Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapyEuropean Journal of Medicinal Chemistry, 2017
- Strategies and challenges for the next generation of antibody–drug conjugatesNature Reviews Drug Discovery, 2017
- Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCsMolecular Pharmaceutics, 2015
- Antibody–drug conjugates as novel anti-cancer chemotherapeuticsBioscience Reports, 2015
- Approaches to Interchain Cysteine-Linked ADC Characterization by Mass SpectrometryMolecular Pharmaceutics, 2014
- Antibody–drug conjugates—A new wave of cancer drugsBioorganic & Medicinal Chemistry Letters, 2014
- Antibody–Drug Conjugates: An Emerging Concept in Cancer TherapyAngewandte Chemie International Edition, 2014
- Antibody–drug conjugatesNature Reviews Drug Discovery, 2013